Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial
Stopped In compliance with current legislation applicable to Clinical Trials, following the instructions of the Spanish Agency for Medicines and Health Products.
Conditions
- Metastatic Thyroid Papillary Carcinoma
- Metastatic Thyroid Follicular Carcinoma
- Metastatic Thyroid Cancer
Interventions
- DRUG: Durvalumab
- DRUG: Tremelimumab
Sponsor
Grupo Espanol de Tumores Neuroendocrinos
Collaborators